BioSpace News Archive

The results of a clinical trial using software from XRHealth, developer and operator of virtual treatment rooms in the metaverse, published in MDPI highlights that the combination of virtual reality and artificial intelligence reduces hot flashes and improves the overall psychological well-being of women with breast and ovarian cancer.

Chemomab Therapeutics, Ltd. today announced the appointment of Mitchell L. Jones , MD, PhD, as Vice President of Corporate Development & Strategy.

Terray Therapeutics today announced the appointment of Bassil Dahiyat, Ph.D., as an Independent Director.

Pathios Therapeutics Limited (“Pathios”), a biotech company focused on developing first-in-class therapies for cancer, today announced that Jeanmarie Guenot , Ph.D., has been appointed as a non-executive director to the company’s board of directors.

CTI BioPharma Corp. (NASDAQ: CTIC) today announced that management will participate in a fireside chat at the JMP Securities Hematology and Oncology Summit at 3:00 p.m. ET.

Aeglea BioTherapeutics, Inc. today announced the appointment of Jeffrey M. Goldberg as president, chief executive officer and member of the board of directors effective November 29, 2022.

AstraZeneca will present 47 abstracts showcasing new data from across its hematology portfolio and clinical pipeline, demonstrating its commitment to redefining care for hard-to-treat blood diseases at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, December 10 to 13, 2022.

Ascletis Pharma Inc. (HKEX: 1672, “Ascletis”) announces today the completion of 180 patient enrollment for the Phase II clinical trial of ASC40 (denifanstat) for treatment of moderate to severe acne. The study is currently still blind.

Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced a clinical trial collaboration and supply agreement (CTCSA) with Pierre Fabre for the BRAF inhibitor encorafenib (BRAFTOVI®) within key international territories.

Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company focused on discovering and developing medicines that are transformational for patients, today announced Karen Anderson as its new Chief People Officer.